 |
| Nina DeLorenzo |
Emergent BioSolutions, life sciences company, has hired Nina DeLorenzo as senior VP-global public affairs.
The 25-year veteran joins the Gaithersburg, MD-based company from French pharmaceuticals giant Sanofi, where she was chief of staff, external affairs in Paris.
Earlier, DeLorenzo served as VP-international affairs at AbbVie, PA director at Pfizer, senior manager international PA at Schering-Plough and senior director communications & PA at PhRMA lobbying group.
She also did a nearly two-year stint at the State Dept. during the Bush II presidency.
At Emergent Bio, DeLorenzo is in charge of external affairs, corporate communications, advocacy and corporate social responsibility.
On April 2, the company unveiled a partnership with the US government to expedite development of a plasma-derived therapy for patients with COVID-19.
It received a $14.5M grant from the Biomedical Advanced Research and Development Authority to fund the effort.
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
